Cardio classics revisited – focus on the role of candesartan

References

• DahlöfBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMVALUE trial groupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• World Health OrganizationCardiovascular disease: prevention and control Accessed on-line at www.who.int, 2009 Apr.
   Google Scholar
• Public Health Agency of CanadaLeading Causes of Death and Hospitalization in Canada. Accessed on-line at http://www.phac-aspc.gc.ca, 2009 Apr.
   Google Scholar
• DzauVJAntmanEMBlackHRThe cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)Circulation2006114252850287017179034
   PubMed Web of Science ®Google Scholar
• MochizukiSDahlöfBShimizuMValsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality studyLancet200736995711431143917467513
   PubMed Web of Science ®Google Scholar
• ONTARGET InvestigatorsYusufSTeoKKTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• TRANSCEND InvestigatorsEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet20083721174118318757085
   PubMed Web of Science ®Google Scholar
• SchraderJLüdersSKulschewskiAMorbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES)Stroke20053661218122615879332
   PubMed Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med2008359121225123718753639
   PubMed Web of Science ®Google Scholar
• DicksteinKKjekshusJOPTIMAAL Steering Committee of the OPTIMAAL Study GroupEffects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist LosartanLancet2002360933575276012241832
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• PfefferMABraunwaldEMoyéLAEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trialN Engl J Med19923276696771386652
   PubMed Web of Science ®Google Scholar
• Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study InvestigatorsLancet199334288758218288104270
   PubMed Web of Science ®Google Scholar
• KøberLTorp-PedersenCCarlsenJEA clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study GroupN Engl J Med199533325167016767477219
   PubMed Web of Science ®Google Scholar
• McMurrayJSolomonSPieperKThe effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)J Am Coll Cardiol200647472673316487836
   PubMedGoogle Scholar
• PittBPoole-WilsonPASegalREffect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE IILancet200035592151582158710821361
   PubMed Web of Science ®Google Scholar
• PittBSegalRMartinezFARandomised trial of losartan versus captopril in patients over 65 with heart failureLancet19973497477529074572
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGValsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programLancet2003362938675976613678868
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet2003362938676777113678869
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet2003362938677277613678870
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet2003362938677778113678871
   PubMed Web of Science ®Google Scholar
• MassieBMCarsonPEMcMurrayJJIrbesartan in patients with heart failure and preserved ejection fractionN Engl J Med2008359232456246719001508
   PubMed Web of Science ®Google Scholar
• FitchettDResults of the ONTARGET and TRANSCEND studies: an update and discussionVasc Health Risk Manag200951212919436659
   PubMedGoogle Scholar
• The ACTIVE Steering CommitteeACTIVE InvestigatorsConnollySRationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular eventsAm Heart J200615161187119316781218
   PubMed Web of Science ®Google Scholar
• CooperCJMurphyTPMatsumotoAStent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trialAm Heart J20061521596616824832
   PubMed Web of Science ®Google Scholar
• SawadaTTakahashiTYamadaHRationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular eventsJ Hum Hypertens200923318819518800142
   PubMed Web of Science ®Google Scholar
• Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance. www.clinicaltrials.gov. Accessed April 2009
   Google Scholar
• The NAVIGATOR Trial Steering CommitteeNateglinide and valsartan in impaired glucose tolerance outcomes research: rationale and design of the NAVIGATOR trial (Abstract)Diabetes200251A116
   Web of Science ®Google Scholar
• HallerHVibertiGCMimranAPreventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) studyJ Hypertens200624240340816508590
   PubMed Web of Science ®Google Scholar
• The Internet Stroke CenterStroke Trials Registry www.strokecenter.org. Accessed April 2009
   Google Scholar
• OgiharaTSarutaTMatsuokaHValsartan in elderly isolated systolic hypertension (VALISH) study: rationale and designHypertens Res200427965766115750259
   PubMed Web of Science ®Google Scholar
• NakayamaKKuwabaraYDaimonMValsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary resultsHypertens Res2008311212818360014
   PubMed Web of Science ®Google Scholar
• SeverPSGradmanAHAziziMManaging cardiovascular and renal risk: the potential of direct renin inhibitionJ Renin Angiotensin Aldosterone Syst2009102657619502253
   PubMed Web of Science ®Google Scholar
• VanderheydenPMLFierensFLPVauquelinGAngiotensin II type 1receptor antagonists. Why do some of them produce insurmountable inhibitionBiochem Pharmacol200060155711077037
   PubMed Web of Science ®Google Scholar
• VauquelinGFierensFLPVanderheydenPMLDistinction between surmountable and insurmountable angiotensin II AT1 receptor antagonistsEpsteinMBrunnerHRAngiotensin II receptor antagonistsPhiladelphia, PAHanley and Belful200010518
   Google Scholar
• VanderheydenPMLFierensFLPDe BackerJPDistinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptorsBr J Pharmacol19991261057106510193788
   PubMed Web of Science ®Google Scholar
• SeversPSHolzgreveHLong-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertensionJ Hum Hypertens199711Suppl 2S69S739331014
   PubMedGoogle Scholar
• New Zealand emedicines and medical devices safety authority data sheet. Available from: www.medsafe.govt.nz/profs/datasheet/a/Atacandtab.htm [Accessed 13 June 2009]
   Google Scholar
• SeversPCandesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blockerJ Hum Hypertens199711Suppl 2S91S959331018
   PubMedGoogle Scholar
• VitDWhiteWRidleyEA forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study IIJ Hum Hypertens20011547548011464257
   PubMed Web of Science ®Google Scholar
• MacgregorGViskopferJAntoniosTFengJUK and Israel Candesartan InvestigatorsEfficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertensionHypertension20003645410988281
   PubMed Web of Science ®Google Scholar
• FogariRMugelliniADerosaGCANDIA (Candesartan and diuretic vs amlodipine in hypertensive patients) Study Group: efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertensionJ Renin Angiotensin Aldosterone Syst20078313914417907102
   PubMed Web of Science ®Google Scholar
• OparilSLevineJZushkeCEffects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study InvestigatorsAm J Cardiol199984328929310496437
   PubMed Web of Science ®Google Scholar
• OparilSCandesartan cilexetil in combination with low-dose hydro-chlorothiazide is effective in severe hypertensionAm J Cardiol19998410A35S41S10588093
   PubMed Web of Science ®Google Scholar
• SeverPClinical profile of the novel angiotensin II type I blocker candesartan cilexetilJ Hypertens Suppl1997156S9S129493121
   PubMedGoogle Scholar
• TaavitsainenPKiukaanniemiKPelkonenOIn vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonistsEur J Clin Pharmacol200056213514010877007
   PubMed Web of Science ®Google Scholar
• LithellPHanssonLSkoogISCOPE Study GroupThe study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• PapademetriouVFarsangCElmfeldtDStudy on cognition and prognosis in the elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE)J Am Coll Cardiol20044461175118015364316
   PubMed Web of Science ®Google Scholar
• SchraderJLudersSKuschewskiAAcute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivorsStroke20033471699170312817109
   PubMed Web of Science ®Google Scholar
• YusufSOstergrebJGersteinHCandesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failureCirculation20051121485315983242
   PubMed Web of Science ®Google Scholar
• Chobanian AbakrisGBlackHCushmanWThe National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension200342120614656957
   PubMed Web of Science ®Google Scholar
• PapadopolousDMakrisTPapademtriouVIs it time to treat pre-hypertension?Hypertens Res20083191681168618971545
   PubMed Web of Science ®Google Scholar
• EganBNesbittSJuliusSPrehypertension: should we be treating with pharmacologic therapy?Ther Adv Cardiovasc Dis20082430531419124429
   PubMedGoogle Scholar
• GargRYusufSOverview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor TrialsJAMA199527318145014567654275
   PubMed Web of Science ®Google Scholar
• The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. ESC guidelinesEur Heart J2008292238822442
   Web of Science ®Google Scholar
• DucharmeASwedbergKPfefferMPrevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programAm Heart J20061521869216838426
   PubMed Web of Science ®Google Scholar
• MaggioniALatiniRCarsonPValsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Am Heart J200514954854715864246
   PubMed Web of Science ®Google Scholar
• WachtellKLehtoMGerdtsEAngiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) studyJ Am Coll Cardiol20054571271915734615
   PubMed Web of Science ®Google Scholar
• MarkusPSchneiderMD*HuaTsushung APhD †BöhmMichaelMD‡WachtellKristianMD, PhD§KjeldsenSverre EMD, PhD||SchmiederRoland EMDPrevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition. A Meta AnalysisJ Am Coll Cardiol2010552299230720488299
   PubMed Web of Science ®Google Scholar
• Jandeleit-DahmKTikellisCReidCWhy blockade of the renin-angiotensin system reduces the incidence of new-onset diabetesJ Hypertens200523346347315716683
   PubMed Web of Science ®Google Scholar
• ShaoJiaqingIwashitaNIkedaFBeneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on β-cell function. Biochemical and biophysical research communications and morphology in db/db miceBiochem Biophys Res Commun200634441224123316650382
   PubMed Web of Science ®Google Scholar
• GillespieEWhiteCKardasMThe impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetesDiabetes Care2005282261226616123505
   PubMed Web of Science ®Google Scholar
• ScheenAPrevention of type 2 diabetes mellitus through inhibition of the Renin–angiotensin systemDrugs200464222537256515516153
   PubMed Web of Science ®Google Scholar
• ElliottWMeyerPIncident diabetes in clinical trials of antihypertensive drugs: a network meta-analysisThe Lancet20073699557201207
   PubMed Web of Science ®Google Scholar
• OgiharaTNakaoKFukuiTEffects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trialHypertension200851239339818172059
   PubMed Web of Science ®Google Scholar
• KasanukiHHagiwaraNHosodaSAngiotensin II receptor blocker-based vs non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE)Eur Heart J200930101203121219346521
   PubMed Web of Science ®Google Scholar
• SuzukiKNakagawaOAizawaYImproved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose toleranceClin Exp Hypertens200830530931418633754
   PubMed Web of Science ®Google Scholar
• BoshJYusufSGerdteinHDREAM Trial Investigators Effect of ramipril on the incidence of diabetesN Engl J Med2006355151551156216980380
   PubMed Web of Science ®Google Scholar
• CaliffRBoolellMHafnerSNAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) TrialAm Heart J2008156462363218946890
   PubMed Web of Science ®Google Scholar
• MitchellKBraamBNavarLHypertensiogenic mechanisms mediated by renal actions of rennin–angiotensin systemHypertension199219Suppl 1I18I271730450
   PubMed Web of Science ®Google Scholar
• LewisEHunsickerLBainRRohdeRThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study GroupN Engl J Med199332920145614628413456
   PubMed Web of Science ®Google Scholar
• LovellHAngiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuriaCochrane Database Syst Rev20011CD00218311279757
   PubMedGoogle Scholar
• StrippoliGCraigMCraigJAntihypertensive agents for preventing diabetic kidney diseaseCochrane Database Syst Rev20054CD00413616235351
   PubMedGoogle Scholar
• LewisEHunsickerLClarkeWCollaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• BrennerBCooperMDezeeuwDRENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• ParvingHLehnertHIrbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med20013451287087811565519
   PubMed Web of Science ®Google Scholar
• StripolliGCraigMDeeksJEffects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic reviewBMJ2004329747082815459003
   PubMedGoogle Scholar
• MackenzieHTroyJRennkeHBrennerBTCV 116 prevents progressive renal injury in rats with extensive renal mass ablationJ Hypertens Suppl1994129S11S167884578
   PubMedGoogle Scholar
• KumagaiHSkataKMatsuuraTComparison of ARB and ACEI for renoprotection in chronic glomerulonephritisNippon Rinsho200260102005201312397699
   PubMedGoogle Scholar
• MurayamaSHiranoTSakaueTLow-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressureHypertens Res200326645345812862201
   PubMed Web of Science ®Google Scholar
• RossingKChristensenPHansenBOptimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over studyDiabetes Care200326115015512502672
   PubMed Web of Science ®Google Scholar
• WeinbergAZappeDAshtonMWeinbergMSafety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot studyAm J Nephrol200424334034515192304
   PubMed Web of Science ®Google Scholar
• SchmeiderRKlingbeilAFleischmannEAdditional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective studyJ Am Soc Nephrol200516103038304516120821
   PubMed Web of Science ®Google Scholar
• BurgessEMuirheadNDecotretPthe SMART (Supra Maximal Atacand Renal Trial) InvestigatorsSupramaximal dose of candesartan in proteinuric renal diseaseJ Am Soc Nephrol200920489390019211712
   PubMed Web of Science ®Google Scholar
• KurokawaKAbeKSarutaTAntiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritisJ Renin Angiotensin Aldosterone Syst20023316717512563567
   PubMed Web of Science ®Google Scholar
• OmotoKTanabeKTokumotoKUse of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunctionTransplantation20037681170117414578748
   PubMed Web of Science ®Google Scholar
• NutaharaKHigashiharaEHorieSCalcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney diseaseNephron Clin Pract2005991c18c2315637459
   PubMedGoogle Scholar
• MogensenCNeldamSTikkanenIfor the CALM Study GroupRandomised controlled trial of dual blockade of rennin – angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM)studyBMJ20003211440144411110735
   PubMed Web of Science ®Google Scholar
• Kincaid-SmithPFairleyKPackhamDDual blockade of the rennin–angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressureNephrol Dial Transplant20041992272227415252156
   PubMed Web of Science ®Google Scholar
• LunoJBarrioVGoicoecheaMEffects of dual blockade of the rennin–angiotensin system in primary proteinuric nephropathiesKidney Int Suppl200282S47S5212410855
   PubMedGoogle Scholar
• RossingKChristensenPJensenBParvingHDual blockade of the rennin–angiotensin system in diabetic nephropathy: a randomized double-blind crossover studyDiabetes Care20022519510011772908
   PubMed Web of Science ®Google Scholar
• AndersenNPoulsenPKnudsenSLong-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II studyDiabetes Care200528227327715677778
   PubMed Web of Science ®Google Scholar
• ChatuverdiNPortaMKleinRDIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trialsLancet200837296471394140218823656
   PubMed Web of Science ®Google Scholar
• SjolieAKleinRPortaMDIRECT Programme Study GroupEffect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialLancet200837296471385139318823658
   PubMed Web of Science ®Google Scholar
• De RosaMLChiarielloMCandesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trialJ Clin Hypertens2009114192200
   PubMed Web of Science ®Google Scholar